Metagenomi Therapeutics reported total assets of $173.70M and total liabilities of $61.13M for the quarter ended Jun 2026, down 36.2% year over year. This balance sheet covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash & EquivalentsCash & Equiv. | 95.67M | 51.65M | 101.90M | 140.60M | 102.56M | 61.18M | 25.12M | 27.39M | 29.20M | 26.85M | 32.77M | 41.72M | 25.31M | 39.03M |
| Short-term InvestmentsInvestments (Current) | 130.58M | 224.85M | 238.74M | 249.47M | 220.92M | 196.78M | 178.14M | 151.34M | 119.08M | 114.86M | 81.64M | |||
| Cash & Current Investments | 95.67M | 51.65M | 101.90M | 271.18M | 327.41M | 299.92M | 274.59M | 248.31M | 225.97M | 204.99M | 184.11M | 160.80M | 140.16M | 120.66M |
| Receivables - NetNet Receivables | 2.00M | 2.10M | 1.65M | 0.59M | 1.26M | 1.01M | 0.90M | 1.00M | 0.31M | |||||
| Receivables | 2.00M | 2.10M | 1.65M | 0.59M | 1.26M | 1.01M | 0.90M | 1.00M | 0.31M | |||||
| Prepaid Assets | 4.64M | 6.16M | 6.01M | 7.12M | 8.40M | 6.21M | 5.82M | 4.75M | 4.43M | 4.40M | 3.80M | |||
| Current Assets | 278.27M | 335.64M | 307.58M | 282.29M | 257.96M | 233.20M | 211.68M | 189.82M | 165.54M | 144.56M | 124.47M | |||
| Non-Current Assets | ||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 21.54M | 20.96M | 20.71M | 19.72M | 17.74M | 16.52M | 15.11M | 13.90M | 12.29M | 11.16M | 9.90M | |||
| Long-Term Investments | 10.68M | 10.68M | 10.68M | 10.58M | 3.45M | 3.45M | 2.15M | 2.15M | 2.15M | 2.15M | 2.15M | |||
| Other Non-Current Assets | 6.07M | 5.25M | 5.25M | 15.99M | 5.25M | 5.25M | 5.25M | 10.78M | 5.25M | 5.25M | 11.31M | 6.03M | 9.71M | 9.80M |
| Non-Current Assets | 86.57M | 79.76M | 78.33M | 76.06M | 66.64M | 64.67M | 60.60M | 58.12M | 55.57M | 52.40M | 49.23M | |||
| Assets | 364.84M | 415.40M | 385.91M | 358.35M | 324.60M | 297.87M | 272.28M | 247.94M | 221.10M | 196.95M | 173.70M | |||
| Liabilities | ||||||||||||||
| Current Liabilities | ||||||||||||||
| Accounts Payables | 1.79M | 6.84M | 3.45M | 3.10M | 0.53M | 2.67M | 2.89M | 1.22M | 1.49M | 2.40M | 2.60M | |||
| Payables | 1.79M | 6.84M | 3.45M | 3.10M | 0.53M | 2.67M | 2.89M | 1.22M | 1.49M | 2.40M | 2.60M | |||
| Accumulated Expenses | 11.47M | 7.08M | 10.98M | 8.84M | 8.42M | 6.12M | 5.92M | 9.90M | 6.72M | 4.69M | 7.60M | |||
| Other Accumulated Expenses | 0.45M | 0.12M | 0.28M | 0.31M | 0.17M | 0.23M | 0.23M | |||||||
| Current Taxes | 3.27M | 3.27M | ||||||||||||
| Current Deferred Revenue | 48.07M | 48.29M | 32.98M | 29.05M | 22.76M | 25.50M | 18.94M | 12.90M | 8.70M | 9.31M | 11.20M | |||
| Total Current Liabilities | 68.86M | 70.70M | 52.81M | 45.69M | 37.31M | 39.89M | 33.27M | 29.58M | 22.93M | 22.50M | 27.63M | |||
| Non-Current Liabilities | ||||||||||||||
| Non-Current Deffered Revenue | 30.93M | 20.31M | 17.33M | 12.43M | 10.24M | 4.37M | 3.55M | 1.90M | 2.99M | 1.64M | ||||
| Preferred Stock Liabilities | 350.76M | 350.76M | 350.76M | 350.76M | ||||||||||
| Operating Leases | 44.80M | 43.68M | 42.55M | 41.38M | 40.19M | 38.83M | 37.48M | 36.09M | 34.63M | 33.08M | 31.49M | |||
| Other Non-Current Liabilities | 5.08M | 5.08M | 3.80M | 3.08M | 2.01M | 2.11M | 2.15M | 1.92M | 1.95M | 1.95M | 2.02M | |||
| Total Non-Current Liabilities | 495.35M | 134.69M | 112.68M | 99.50M | 87.73M | 83.10M | 74.30M | 67.57M | 60.55M | 57.22M | 59.12M | |||
| Total Liabilities | 500.43M | 139.77M | 116.49M | 102.58M | 89.74M | 85.21M | 76.45M | 69.49M | 62.51M | 59.17M | 61.13M | |||
| Shareholder's Equity | ||||||||||||||
| Common Equity | -90.01M | -102.54M | -0.12M | -135.58M | 275.63M | 269.42M | 255.77M | 234.86M | 212.66M | 195.83M | 178.45M | 158.60M | 137.79M | 112.57M |
| Liabilities and Shareholders Equity | 364.84M | 415.40M | 385.91M | 358.35M | 324.60M | 297.87M | 272.28M | 247.94M | 221.10M | 196.95M | 173.70M | |||
| Retained Earnings | -144.94M | -170.10M | -180.83M | -199.60M | -223.00M | -248.04M | -267.95M | -288.34M | -310.87M | -333.93M | -361.41M |
Pull Metagenomi Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=MGX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "MGX", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=MGX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();